Aldeyra The Stock
Aldeyra The
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Todd C. Brady
- Employees
- 6
- Market cap
- $42 M
- IPO
- 02/05/2014
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic…
Aldeyra The stock: price history
1D
-5.0%
1W
-23.6%
1M
-48.9%
6M
-61.1%
YTD
-86.5%
1Y
-87.0%
2Y
-87.4%
5Y
-91.6%
10Y
-89.6%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~3% weaker price swings than usual
Ask the agents about Aldeyra The
Analyst assessment of Aldeyra The
PRICE TARGET LOW
US$7.00
CONSENSUS
US$9.67
MEDIAN
US$10.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
18
BUY
1
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 30/09/2026
Aldeyra The stock metrics
P/E
-1.81
P/B
1.11
EV/EBITDA
0.13
RETURN ON EQUITY
-14.4%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.1%
FLOAT SHARES
48,948,858
AVG. DAILY VOLUME (30D)
1,597,887
Insider transactions (SEC)
Brady Todd C
Institutional holders
Comparable stocks
Frequently asked questions about Aldeyra The stock
What does Aldeyra The do?
Aldeyra The is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Todd C. Brady, the company employs around 6 people.
The IPO was on 02/05/2014; the stock trades on NASDAQ under the ticker ALDX.
What do analysts say about Aldeyra The stock?
19 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$9.67, ranging from US$7.00 to US$12.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Aldeyra The report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does Aldeyra The pay a dividend?
No, Aldeyra The currently does not pay a dividend.
Which stocks are comparable to Aldeyra The?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aldeyra The stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aldeyra The against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.